Study of CYFENDUS vaccine for preventing anthrax after exposure
Part of Infections clinical trials.
This study follows people who received the CYFENDUS vaccine to prevent anthrax after a large-scale exposure event. It will check how well the vaccine works and if there are any safety concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received the CYFENDUS vaccine for anthrax prevention.
- The vaccine was given because of a large-scale anthrax exposure event in the United States.
- You may have received antibiotics along with the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (doctors follow people and record outcomes) for patients with systemic anthrax who received AIGIV from the CDC. It aims to learn how safe AIGIV is and what clinical outcomes patients experience after treatment.
This study observes people in the U.S. who have been treated with a specific anthrax drug (raxibacumab) from the national emergency supply. It helps doctors learn more about how the drug works in real-world cases of anthrax infection.
This study looks at how safe and helpful raxibacumab is for people who are sick with inhalational anthrax after being exposed in a large incident. It includes all ages and also includes pregnant and breastfeeding people, focusing on outcomes from standard emergency clinical care.
This trial studies how safe and potentially helpful ANTHRASIL (AIGIV) is for people who have inhalational anthrax after exposure to a known source. If you have suspected or confirmed inhalational anthrax and were treated with AIGIV, you may be able to join this safety-and-benefit study.
This study tests an experimental vaccine to protect against plague. It's for healthy adults 18 to 55 who haven't had plague or the vaccine before. The goal is to see if the vaccine is safe and creates a strong immune response.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
Hear when a new Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.